From Yahoo Finance: 2025-05-08 10:25:00

Truist cuts Ultragenyx’s price target to $100 from $140, citing tampered outlook for gene therapy programs. Q1 results were in-line, and management reaffirmed FY25 revenue guidance. Buy rating maintained. Protect your portfolio against market uncertainty with real-time financial news from TheFly. Insider trading stocks available on TipRanks. Visit TipRanks for more on Ultragenyx. Disclaimer and disclosure information available.



Read more at Yahoo Finance: Ultragenyx price target lowered to $100 from $140 at Truist